Characterization and plasma measurement of the WE-14 peptide in patients with pheochromocytoma

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Guillemot, Johann ^a,b,c,d   Guérin, Marlène ^a,b,c   Thouënnon, Erwan ^a,b,c   Montéro Hadjadje, Maité ^a,b,c   Leprince, Jérôme ^a,b,c   Lefebvre, Hervé ^a,b,c,e   Klein, Marc ^f   Muresan, Mihaela ^g   Anouar, Youssef ^a,b,c   Yon, Laurent ^a,b,c  

^a Université de Rouen   (France)

^b NORMANDIE UNIVERSITÉ   (France)

^c UNIVERSITY OF ROUEN   (France)

^d CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^e ROUEN UNIVERSITY HOSPITAL   (France)

^f CHU NANCY BRABOIS   (France)

^g Bon Secours Hospital   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; PEPTIDE EM66; PEPTIDE WE 14; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASSAY; CANCER PATIENT; CANCER SURGERY; CELL HETEROGENEITY; CHROMAFFIN CELL; CHROMOGRANIN A ASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; EM66 ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NEUROENDOCRINE TUMOR; PARAGANGLIOMA; PEPTIDE ANALYSIS; PHEOCHROMOCYTOMA; PROTEIN BLOOD LEVEL; SENSITIVITY ANALYSIS; WE 14 ASSAY;

ADRENAL GLAND NEOPLASMS; ADULT; AGED; BIOLOGICAL MARKERS; CHROMAFFIN CELLS; CHROMOGRANIN A; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; NEUROENDOCRINE TUMORS; PEPTIDES; PHEOCHROMOCYTOMA; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84895747139     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088698     Document Type: Article

References (52)

1. Fischer-Colbrie R, Laslop A, Kirchmair R (1995) Secretogranin II: molecular properties, regulation of biosynthesis and processing to the neuropeptide secretoneurin. Prog Neurobiol 46: 49-70.
2. Winkler H, Fischer-Colbrie R (1992) The chromogranins A and B: the first 25 years and future perspectives. Neuroscience 49: 497-528.
3. Helle KB (2004) The granin family of uniquely acidic proteins of the diffuse neuroendocrine system: comparative and functional aspects. Biol Rev Camb Philos Soc 79: 769-794.
4. Guerin M, Guillemot J, Thouennon E, Pierre A, El-Yamani FZ, et al. (2010) Granins and their derived peptides in normal and tumoral chromaffin tissue: Implications for the diagnosis and prognosis of pheochromocytoma. Regul Pept 165: 21-29.
5. Zhao E, Zhang D, Basak A, Trudeau VL (2009) New insights into granin-derived peptides: evolution and endocrine roles. Gen Comp Endocrinol 164: 161-174.
6. Rosa P, Gerdes HH (1994) The granin protein family: markers for neuroendocrine cells and tools for the diagnosis of neuroendocrine tumors. J Endocrinol Invest 17: 207-225.
7. Taupenot L, Harper KL, O'Connor DT (2003) The chromogranin-secretogranin family. N Engl J Med 348: 1134-1149. (Pubitemid 36337325)
8. Ferrari L, Seregni E, Bajetta E, Martinetti A, Bombardieri E (1999) The biological characteristics of chromogranin A and its role as a circulating marker in neuroendocrine tumours. Anticancer Res 19: 3415-3427. (Pubitemid 30000197)
9. O'Connor DT, Deftos LJ (1986) Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med 314: 1145-1151. (Pubitemid 16138661)
10. Baudin E, Bidart JM, Bachelot A, Ducreux M, Elias D, et al. (2001) Impact of chromogranin A measurement in the work-up of neuroendocrine tumors. Ann Oncol 12 Suppl 2: S79-82. (Pubitemid 33069692)
11. Guignat L, Bidart JM, Nocera M, Comoy E, Schlumberger M, et al. (2001) Chromogranin A and the alpha-subunit of glycoprotein hormones in medullary thyroid carcinoma and phaeochromocytoma. Br J Cancer 84: 808-812. (Pubitemid 32275655)
12. Cunningham RT, Pogue KM, Curry WJ, Johnston CF, Sloan JM, et al. (1999) Immunostaining for vasostatin I distinguishes between ileal and lung carcinoids. J Pathol 187: 321-325. (Pubitemid 29064158)
13. Sekiya K, Ghatei MA, Salahuddin MJ, Bishop AE, Hamid QA, et al. (1989) Production of GAWK (chromogranin-B 420-493)-like immunoreactivity by endocrine tumors and its possible diagnostic value. J Clin Invest 83: 1834-1842. (Pubitemid 19148851)
14. Yasuda D, Iguchi H, Funakoshi A, Wakasugi H, Sekiya K, et al. (1993) Comparison of plasma pancreastatin and GAWK concentrations, presumed processing products of chromogranin A and B, in plasma of patients with pancreatic islet cell tumors. Horm Metab Res 25: 593-595. (Pubitemid 23344313)
15. Vieau D, Rojas-Miranda A, Verley JM, Lenne F, Bertagna X (1991) The secretory granule peptides 7B2 and CCB are sensitive biochemical markers of neuro-endocrine bronchial tumours in man. Clin Endocrinol (Oxf) 35: 319-325.
16. Eder U, Fischer-Colbrie R, Kogner P, Leitner B, Bjellerup P, et al. (1998) Levels and molecular forms of chromogranins in human childhood neuroblastomas and ganglioneuromas. Neurosci Lett 253: 17-20. (Pubitemid 28417008)
17. Ischia R, Gasser RW, Fischer-Colbrie R, Eder U, Pagani A, et al. (2000) Levels and molecular properties of secretoneurin-immunoreactivity in the serum and urine of control and neuroendocrine tumor patients. J Clin Endocrinol Metab 85: 355-360. (Pubitemid 32268837)
18. Ischia R, Hobisch A, Bauer R, Weiss U, Gasser RW, et al. (2000) Elevated levels of serum secretoneurin in patients with therapy resistant carcinoma of the prostate. J Urol 163: 1161-1164; discussion 1164-1165.
19. Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, et al. (2002) Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346: 1459-1466. (Pubitemid 34755714)
20. Karasek D, Frysak Z, Pacak K (2010) Genetic testing for pheochromocytoma. Curr Hypertens Rep 12: 456-464.
21. Thouennon E, Pierre A, guillemot J, Yon L, Eisenhofer G, et al. (2009) Genetic markers for the diagnosis and prognosis of pheochromocytoma. Expert Rev Endocrinol Metab 4: 45-52.
22. Vicha A, Musil Z, Pacak K (2013) Genetics of pheochromocytoma and paraganglioma syndromes: new advances and future treatment options. Curr Opin Endocrinol Diabetes Obes 20: 186-191.
23. Amar L, Bertherat J, Baudin E, Ajzenberg C, Bressac-de Paillerets B, et al. (2005) Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol 23: 8812-8818. (Pubitemid 46211527)
24. Andersen KF, Altaf R, Krarup-Hansen A, Kromann-Andersen B, Horn T, et al. (2011) Malignant pheochromocytomas and paragangliomas - the importance of a multidisciplinary approach. Cancer Treat Rev 37: 111-119.
25. Anouar Y, Jegou S, Alexandre D, Lihrmann I, Conlon JM, et al. (1996) Molecular cloning of frog secretogranin II reveals the occurrence of several highly conserved potential regulatory peptides. FEBS Lett 394: 295-299. (Pubitemid 26341461)
26. 187-252) in adult and fetal human adrenal glands using antibodies raised against the human recombinant peptide. J Clin Endocrinol Metab 83: 2944-2951.
27. Guillemot J, Ait-Ali D, Turquier V, Montero-Hadjadje M, Fournier A, et al. (2006) Involvement of multiple signaling pathways in PACAP-induced EM66 secretion from chromaffin cells. Regul Pept 137: 79-88. (Pubitemid 44751198)
28. Montero-Hadjadje M, Pelletier G, Yon L, Li S, Guillemot J, et al. (2003) Biochemical characterization and immunocytochemical localization of EM66, a novel peptide derived from secretogranin II, in the rat pituitary and adrenal glands. J Histochem Cytochem 51: 1083-1095. (Pubitemid 36919986)
29. Guillemot J, Anouar Y, Montero-Hadjadje M, Grouzmann E, Grumolato L, et al. (2006) Circulating EM66 is a highly sensitive marker for the diagnosis and follow-up of pheochromocytoma. Int J Cancer 118: 2003-2012.
30. Guillemot J, Thouennon E, Guerin M, Vallet-Erdtmann V, Ravni A, et al. (2012) Differential expression and processing of secretogranin II in relation to the status of pheochromocytoma: implications for the production of the tumoral marker EM66. J Mol Endocrinol 48: 115-127.
31. Yon L, Guillemot J, Montero-Hadjadje M, Grumolato L, Leprince J, et al. (2003) Identification of the secretogranin II-derived peptide EM66 in pheochromocytomas as a potential marker for discriminating benign versus malignant tumors. J Clin Endocrinol Metab 88: 2579-2585. (Pubitemid 36724427)
32. Montero-Hadjadje M, Vaudry H, Turquier V, Leprince J, Do Rego JL, et al. (2002) Localization and characterization of evolutionarily conserved chromogranin A-derived peptides in the rat and human pituitary and adrenal glands. Cell Tissue Res 310: 223-236. (Pubitemid 36015573)
33. Guillemot J, Compagnon P, Cartier D, Thouennon E, Bastard C, et al. (2009) Metoclopramide stimulates catecholamine- and granin-derived peptide secretion from pheochromocytoma cells through activation of serotonin type 4 (5-HT4) receptors. Endocr Relat Cancer 16: 281-290.
34. Conlon JM, Hamberger B, Grimelius L (1992) Isolation of peptides arising from the specific posttranslational processing of chromogranin A and chromogranin B from human pheochromocytoma tissue. Peptides 13: 639-644.
35. Curry WJ, Shaw C, Johnston CF, Thim L, Buchanan KD (1992) Isolation and primary structure of a novel chromogranin A-derived peptide, WE-14, from a human midgut carcinoid tumour. FEBS Lett 301: 319-321.
36. Gleeson CM, Curry WJ, Johnston CF, Buchanan KD (1996) Occurrence of WE-14 and chromogranin A-derived peptides in tissues of the human and bovine gastro-entero-pancreatic system and in human neuroendocrine neoplasia. J Endocrinol 151: 409-420. (Pubitemid 26405589)
37. Hanna FW, Ardill JE, Johnston CF, Cunningham RT, Curry WJ, et al. (1997) Regulatory peptides and other neuroendocrine markers in medullary carcinoma of the thyroid. J Endocrinol 152: 275-281. (Pubitemid 27115777)
38. Heaney AP, Curry WJ, Pogue KM, Armstrong VL, Mirakhur M, et al. (2000) Immunohistochemical evaluation of the post-translational processing of chromogranin A in human pituitary adenomas. Pituitary 3: 67-75. (Pubitemid 32798986)
39. Leprince J, Gandolfo P, Thoumas JL, Patte C, Fauchere JL, et al. (1998) Structure-activity relationships of a series of analogues of the octadecaneuropeptide ODN on calcium mobilization in rat astrocytes. J Med Chem 41: 4433-4438. (Pubitemid 28516442)
40. Curry WJ, Quinn JG, Brockbank S, Miller V, McVicar C, et al. (2004) Comparative Studies of the Chromogranin A-Derived Neuropeptide WE-14. Curr Med Chem 4: 213-219. (Pubitemid 39161874)
41. d'Herbomez M, Forzy G, Bauters C, Tierny C, Pigny P, et al. (2007) An analysis of the biochemical diagnosis of 66 pheochromocytomas. Eur J Endocrinol 156: 569-575. (Pubitemid 46796524)
42. Stridsberg M, Eriksson B, Oberg K, Janson ET (2003) A comparison between three commercial kits for chromogranin A measurements. J Endocrinol 177: 337-341. (Pubitemid 36656407)
43. Sanduleanu S, De Bruine A, Stridsberg M, Jonkers D, Biemond I, et al. (2001) Serum chromogranin A as a screening test for gastric enterochromaffin- like cell hyperplasia during acid-suppressive therapy. Eur J Clin Invest 31: 802-811. (Pubitemid 34203475)
44. Stridsberg M, Oberg K, Li Q, Engstrom U, Lundqvist G (1995) Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol 144: 49-59.
45. Borch K, Stridsberg M, Burman P, Rehfeld JF (1997) Basal chromogranin A and gastrin concentrations in circulation correlate to endocrine cell proliferation in type-A gastritis. Scand J Gastroenterol 32: 198-202. (Pubitemid 27105292)
46. Spadaro A, Ajello A, Morace C, Zirilli A, D'Arrigo G, et al. (2005) Serum chromogranin-A in hepatocellular carcinoma: diagnostic utility and limits. World J Gastroenterol 11: 1987-1990. (Pubitemid 40520997)
47. Nobels FR, Kwekkeboom DJ, Coopmans W, Schoenmakers CH, Lindemans J, et al. (1997) Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 82: 2622-2628. (Pubitemid 27337883)
48. Loo BM, Marniemi J, Jula A (2011) Evaluation of multiplex immunoassays, used for determination of adiponectin, resistin, leptin, and ghrelin from human blood samples, in comparison to ELISA assays. Scand J Clin Lab Invest 71: 221-226.
49. Kim YW, Bae SM, Kim IW, Liu HB, Bang HJ, et al. (2012) Multiplexed bead-based immunoassay of four serum biomarkers for diagnosis of ovarian cancer. Oncol Rep 28: 585-591.
50. Därr R, Pamporaki C, Peitzsch M, Miehle K, Prejbisz A, et al. (2013) Biochemical diagnosis of phaeochromocytoma using plasma-free normetanephrine, metanephrine and methoxytyramine: importance of supine sampling under fasting conditions. Clin Endocrinol doi: 10.1111/cen.12327.
51. Neumann HP (2002) Imaging vs biochemical testing for pheochromocytoma. Jama 288: 314-315; author reply 315.
52. Sawka AM, Gafni A, Thabane L, Young WF Jr (2004) The economic implications of three biochemical screening algorithms for pheochromocytoma. J Clin Endocrinol Metab 89: 2859-2866. (Pubitemid 38766377)